RoverMed BioSciences

RoverMed BioSciences operated in the biotechnology sector as a developer of targeted drug delivery technology. Founded in October 2016, the company focused on creating solutions for life-saving drugs. Its primary innovation was a Crystalline Ultra-Small Particle (CUSP) technology, a nanocapsule platform designed to deliver therapeutics, including DNA, RNA, and proteins, to the most challenging disease sites within the body.

The core of RoverMed's offering was its 20-nanometer nanocapsule, which was engineered to transport its payload across biological barriers and into the nucleus of targeted diseased cells, a significant advancement over technologies like liposomes. This capability aimed to enhance the efficacy of biologic drugs that require precise, cell-specific delivery to treat diseases, particularly solid cancers. The technology was developed to serve biotechnology and pharmaceutical companies by improving their drug development and delivery systems. The business model was centered on forming partnerships, which would provide immediate revenue streams.

The company successfully raised a total of $1.2M to $2.2M in funding over several rounds from investors including Gopher Angels, St. Louis Arch Angels, 701 Fund, Alpha Impact 8, and Blackbox (Palo Alto). In a significant milestone, RoverMed BioSciences was acquired by Asklepios BioPharmaceutical, Inc. (AskBio) on September 17, 2019. AskBio, a gene therapy platform company, acquired RoverMed's technology assets to integrate the nanocapsule delivery system into its AAV gene therapy platform, enhancing its ability to deliver therapeutic molecules with greater stability and specificity.

Keywords: drug delivery, nanotechnology, biotechnology, nanocapsule, cancer treatment, gene therapy, biologics, drug development, CUSP technology, therapeutics